CSF2 and acute respiratory distress syndrome: On the other hand, the FDA-approved recombinant GM-CSF, Sargramostim (Leukine®), is currently being investigated in a phase IV trial as an adjuvant therapy to restore alveolar anti-inflammatory macrophages to manage acute hypoxic respiratory failure and ARDS (NCT04326920) (57, 110, 276).